Muted Outlook – But Better Than Expected!
Called out a month ago – and now it shows: Even a weak outlook is enough for a positive market reaction!
Wegovy’s potential remains enormous long-term – oral weight loss pill and Hims collaboration as strategic advantages!
Reading Time: 1 minute
Novo Nordisk has positively surprised in Q1 2025 despite growing competition from copycat products: The profit exceeded analysts' recently lowered expectations. At the same time, the legal protection periods for legal copies of Wegovy will end this May, which should alleviate the competitive environment. The introduction of the first oral weight loss pill is already on the brink of the next wave of innovation. Additionally, the partnership with Hims & Hers is strategically wise – it provides access to new digital distribution channels and...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
